Biochemical disease-free survival following transperineal iodine-125 or palladium-108 prostate implantation in clinically localized prostate cancer

被引：0
|
作者：
Meek, AG
Park, TL
Kim, A
Waltzer, W
Munkelwitz, R
Adler, H
机构：
来源：
RADIOLOGY | 2000年 / 217卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
187RO
引用
收藏
页码：143 / 144
页数：2
相关论文
共 50 条
  • [21] Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer
    Han, M
    Partin, AW
    Piantadosi, S
    Epstein, JI
    Walsh, PC
    JOURNAL OF UROLOGY, 2001, 166 (02): : 416 - 419
  • [22] Disease control following iodine-125 seed brachytherapy in low risk prostate cancer.
    Morton, G
    Choo, R
    Loblaw, DA
    RADIOTHERAPY AND ONCOLOGY, 2004, 72 : S51 - S51
  • [23] Long term outcomes following iodine-125 monotherapy for localized prostate cancer: The cookridge 10 year results
    Ash, D.
    Al-Qaisieh, B.
    Gould, K.
    Carey, B.
    Bottomley, D.
    Henry, A. M.
    CLINICAL ONCOLOGY, 2007, 19 (03) : S18 - S18
  • [24] Long-term results of retropubic permanent (125)iodine implantation of the prostate for clinically localized prostatic cancer
    Zelefsky, MJ
    Whitmore, WF
    JOURNAL OF UROLOGY, 1997, 158 (01): : 23 - 29
  • [25] Long term outcomes following iodine-125 monotherapy for localized prostate cancer: The results of a large European series
    Henry, A. M.
    Al-Qaisieh, B.
    Gould, K.
    Carey, B.
    Bottomley, D.
    Ash, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S332 - S332
  • [26] Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).
    Sweeney, Christopher
    Xie, Wanling
    Regan, Meredith M.
    Nakabayashi, Mari
    Buyse, Marc E.
    Clarke, Noel W.
    Collette, Laurence
    Dignam, James J.
    Fizazi, Karim
    Habibian, Muriel
    Halabi, Susan
    Kantoff, Philip W.
    Parulekar, Wendy R.
    Sandler, Howard M.
    Sartor, Oliver
    Soule, Howard R.
    Sydes, Matthew Robert
    Tombal, Bertrand F.
    Williams, Scott G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] FIFTEEN-YEAR BIOCHEMICAL RELAPSE-FREE SURVIVAL, CAUSE-SPECIFIC SURVIVAL, AND OVERALL SURVIVAL FOLLOWING I125 PROSTATE BRACHYTHERAPY IN CLINICALLY LOCALIZED PROSTATE CANCER: SEATTLE EXPERIENCE
    Sylvester, John E.
    Grimm, Peter D.
    Wong, Jason
    Galbreath, Robert W.
    Merrick, Gregory
    Blasko, John C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : 376 - 381
  • [28] Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer
    Benko, Goran
    Spajic, Borislav
    Kruslin, Bozo
    Tomas, Davor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (04) : 468 - 474
  • [29] Determinants of disease control following iodine-125 permanent seed brachytherapy in low risk prostate cancer
    Morton, G
    Loblaw, DA
    RADIOTHERAPY AND ONCOLOGY, 2005, 75 : S38 - S39
  • [30] Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy
    Brandli, DW
    Koch, MO
    Foster, RS
    Bihrle, R
    Gardner, TA
    BJU INTERNATIONAL, 2003, 92 (01) : 19 - 22
12345